RxDoctor Payments Data

Emily Howerton

Family · Lakeway, TXNPI 1073291761

Payments from drug & device makers

$1,004in general payments, 2019–2025

Across 40 payments — averaging $25.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$314
  • Boehringer Ingelheim$191
  • Axsome Therapeutics, Inc.$125
  • Exact Sciences$122
  • GSK$64
  • Astellas Pharma US Inc$45
  • plus $143 from 6 others

What the payments were for

  • Food & beverage$1,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,004 in reported general payments places this provider in the 65th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$76,889
Medicare patients
356
Services billed
1,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide30$30,163
JardianceEmpagliflozin19$25,682
EliquisApixaban11$12,465
XareltoRivaroxaban13$8,641
Levothyroxine Sodium124$1,579
Bupropion XlBupropion Hcl83$1,467
CholestyramineCholestyramine (With Sugar)12$1,334
Mirtazapine50$1,174
Liothyronine Sodium26$1,018
Estradiol31$960
Celecoxib34$923
Rosuvastatin Calcium35$862
Ipratropium Bromide27$832
Albuterol Sulfate HfaAlbuterol Sulfate21$802
Gabapentin51$799

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$314$30,16330 claims
Boehringer IngelheimJardiance$191$25,68219 claims
PfizerEliquis$23$12,46511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 15,456 family providers in Texas.

Other family in Lakeway

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →